Two of the leading adversaries in the battle to own CRISPR, the powerful gene-editing tool, took the stage together at a genetic medicine conference here, and they couldn’t have been more polite — or more forward-looking.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.